Fig. 4.

Relationship between baseline NfL and disability progression during the controlled treatment period in each treatment arm of OPERA I and II (a) and ORATORIO (e). High or low NfL was determined by levels above or below the baseline median. NfL elevation at baseline was prognostic for CDP24 only in persons with RMS without acute disease activity receiving IFNβ-1a (c) and in persons with PPMS receiving placebo therapy (e). Baseline NfL was not predictive of CDP24 in persons receiving ocrelizumab treatment (b, d, and f). P values are shown for log-rank tests comparing high vs. low NfL groups. IFN = interferon; NfL = neurofilament light; OCR = ocrelizumab; PBO = placebo; CDP24 = 24-week confirmed disability progression; PPMS = primary progressive multiple sclerosis; RMS = relapsing multiple sclerosis; BL = baseline; H = high; L = low.